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Background: Perfusion-cardiovascular magnetic resonance (CMR) is generally accepted as an alternative to SPECT
to assess myocardial ischemia non-invasively. However its performance vs gated-SPECT and in sub-populations is
not fully established. The goal was to compare in a multicenter setting the diagnostic performance of perfusion-
CMR and gated-SPECT for the detection of CAD in various populations using conventional x-ray coronary
angiography (CXA) as the standard of reference.
Methods: In 33 centers (in US and Europe) 533 patients, eligible for CXA or SPECT, were enrolled in this
multivendor trial. SPECT and CXA were performed within 4 weeks before or after CMR in all patients. Prevalence of
CAD in the sample was 49% and 515 patients received MR contrast medium. Drop-out rates for CMR and SPECT
were 5.6% and 3.7%, respectively (ns). The study was powered for the primary endpoint of non-inferiority of CMR vs
SPECT for both, sensitivity and specificity for the detection of CAD (using a single-threshold reading), the results for
the primary endpoint were reported elsewhere. In this article secondary endpoints are presented, i.e. the diagnostic
performance of CMR versus SPECT in subpopulations such as multi-vessel disease (MVD), in men, in women, and in
patients without prior myocardial infarction (MI). For diagnostic performance assessment the area under the
receiver-operator-characteristics-curve (AUC) was calculated. Readers were blinded versus clinical data, CXA, and
imaging results.
Results: The diagnostic performance (= area under ROC=AUC) of CMR was superior to SPECT (p = 0.0004, n = 425)
and to gated-SPECT (p = 0.018, n = 253). CMR performed better than SPECT in MVD (p = 0.003 vs all SPECT, p = 0.04
vs gated-SPECT), in men (p = 0.004, n = 313) and in women (p = 0.03, n = 112) as well as in the non-infarct patients
(p = 0.005, n = 186 in 1–3 vessel disease and p= 0.015, n = 140 in MVD).* Correspondence: jurg.schwitter@chuv.ch
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http://www.jcmr-online.com/content/14/1/61Conclusion: In this large multicenter, multivendor study the diagnostic performance of perfusion-CMR to detect
CAD was superior to perfusion SPECT in the entire population and in sub-groups. Perfusion-CMR can be
recommended as an alternative for SPECT imaging.
Trial registration: ClinicalTrials.gov, Identifier: NCT00977093
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Early detection of coronary artery disease (CAD) and in
particular of myocardial ischemia remains a major chal-
lenge even with the advent of novel non-invasive im-
aging techniques and further development of existing
modalities. An increasing number of cardiovascular
magnetic resonance (CMR) studies documented a high
diagnostic performance of perfusion-CMR vs conven-
tional x-ray coronary angiography (CXA) [1-9] and
showed its prognostic value [10,11]. In comparison with
CXA, for both, perfusion-CMR [12,13] as well as for
SPECT, cost-effectiveness was demonstrated [14,15].
However, for several sub-groups of patients the diagnos-
tic performance of perfusion-CMR and its potential su-
periority over SPECT is not well established. The first
study of the MR-IMPACT program [2] designed for
dose-finding was the largest perfusion-CMR trial at its
time and demonstrated equal performance vs SPECT in
the head-to-head comparison, and demonstrated super-
iority of CMR when compared versus the entire SPECT
population. The MR-IMPACT II was designed to com-
pare the diagnostic performance of CMR vs SPECT for
the detection of CAD (defined as ≥50% diameter reduc-
tion of coronary vessels in CXA) in a large international
multicenter, multivendor design at a fixed contrast
medium (CM) dose. The primary end-point of MR-
IMPACT II was the comparison of sensitivity and speci-
ficity of perfusion-CMR to detect CAD on CXA vs
SPECT based on a single-point threshold reading. In this
comparison, perfusion-CMR was more sensitive, but less
specific for the detection of CAD in comparison with
SPECT [16]. This single-threshold reading assesses diag-
nostic performance on a single point on the ROC curve,
thus, rendering results susceptible for the reading
threshold [17]. The comparison of test performances by
means of the areas under the ROC curves (AUC) avoids
such potential bias [17]. Therefore, we analyzed as a pre-
defined secondary end-point of the MR-IMPACT II the
AUCs for perfusion-CMR and SPECT for the entire study
population. Additional sub-group analyses assessed the
diagnostic performance in patients studied by gated-
SPECT, in patients without prior myocardial infarctions
(MI) with single- or multi-vessel disease, as well as in men
and in women. In addition, the primary end-point was also
recalculated for a single-point reading at the optimum
threshold as derived from the AUC analyses.Methods
Study design and patient population
This phase III clinical trial was conducted at 33 centers
in Europe and the US. Eligible patients were those
scheduled for a conventional CXA and/or a SPECT
examination for clinical reasons. Before study entry all
patients had to agree to undergo all 3 imaging studies.
As no interventions were allowed on the coronary arter-
ies in the time period between the 3 tests, most patients
underwent CXA as the last test, i.e. after having had the
CMR and SPECT study. Exclusion criteria were: Acute
MI (<2 weeks prior to study enrolment), history of cor-
onary artery bypass grafting, unstable angina pectoris,
decompensated heart failure, contraindications for ad-
enosine and/or CM, and severe arrhythmias (atrial fibril-
lation, bigeminus, >15 extrasystoles/min) considered to
compromise quality of CMR imaging. The study was
conducted according to the Declaration of Helsinki, the
principles of Good Clinical Practice, and was approved
by the Health Authorities and the local Ethics Commit-
tee of each participating institution. All patients gave
written informed consent before study participation.
Efficacy measures
As a pre-defined secondary endpoint of the trial, the
AUCs for perfusion-CMR and SPECT were compared
for the assessment of the diagnostic performances of
CMR and SPECT to detect CAD thereby determining
test performances over a range of thresholds [17]. In
addition, the ROC approach was also used to assess the
test performances in multi-vessel disease (MVD)
patients, in men and in women, as well as in the patient
population without prior MI. As reported elsewhere, for
the primary end-point of MR-IMPACT II a single
threshold reading was used to assess sensitivity and spe-
cificity of CMR and SPECT to detect CAD [16].
Standard of reference - definition of CAD
Two criteria were combined to define CAD by the
standard of reference: 1). The presence of a ≥50% diam-
eter stenosis in quantitative coronary angiography in 2
orthogonal planes (≥75% area reduction) as was used in
previous studies [1-3,18] present in ≥1 coronary artery
of ≥2 mm diameter using a core laboratory (Cleveland
Clinic Foundation, Cleveland, USA). This criterion
accounted for 94.6% of all CAD positive patients in this
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Thus, patients with a history of MI were categorized as
CAD positive even in the absence of stenosed coronary
arteries (e.g. after coronary artery stenting in the setting
of acute MI). This criterion allowed to correctly assign
patients with a perfusion deficit (=hypoperfusion of scar
tissue) to the group of CAD positive patients. This cri-
terion accounted for 5.4% of patients with CAD. Con-
versely, patients with a history of successful PCI/stenting
(with a residual stenosis ≤50% in the actual CXA) and
without a history of MI do not fulfill the definition of
CAD (and are assumed to yield normal perfusion stud-
ies). For the sub-analysis of patients without MI, the
patients with a history of prior MI were excluded. Ves-
sels of <2 mm diameter were not considered for defin-
ition of CAD, since such small vessels are in general not
revascularized (e.g. no stents available for <2 mm
vessels).CMR
In 1.5 T scanners of various vendors breath-hold MR
first-pass perfusion examinations were performed. The
patients had to refrain from coffee, tea, chocolate or
other caffeinated beverages and food for at least 24 h be-
fore the CMR exam. After 3 minutes of an adenosine in-
fusion (0.14 mg/min/kg IV) a bolus of 0.075 mmol/kg
Gd-DTPA-BMA (Omniscan, GE Healthcare, US) was
injected into a peripheral vein with power-injectors at
5 ml/sec (followed by a 25 ml saline flush) during a
breath-hold. A CM dose of 0.075 mmol/kg was chosen
according to recommendations of the food and drug ad-
ministration (FDA) to test the minimal effective dose.
During bolus arrival, 3 short-axis slices were acquired
every heart beat at ¼, ½, and 3/4 of the left ventricular
(LV) long axis (non-slice selective 90°-preparation, fast
gradient-echo acquisition with an echo-planar compo-
nent where available; spatial resolution: 2-3 mm x 2-
3 mm, slice thickness 8-10 mm). At the same locations,
at 10 and 25 minutes after the stress imaging, a rest per-
fusion imaging at the same CM dose and a late enhance-
ment study (with the inversion time nulling normal
myocardium) were performed, respectively.Perfusion-CMR analyses
CMR data were analyzed visually by 3 blinded readers in
an independent core laboratory (Independent Review
Center, GE Healthcare, former Nycomed Amersham Im-
aging, Princeton, USA). The 3 readers were blinded with
respect to any clinical information of the patients or
results of the other examinations.
The ROC analysis was used to compare the diagnostic
performance of CMR and SPECT evaluating the test
performance over the full range of thresholds. For theROC analysis, 16 segments/heart (represented by bulls
eyes not including apical segment 17) were graded each
as showing severely abnormal stress perfusion (=3;
defined as myocardium being black at the peak bolus),
or moderately abnormal defect (=2; myocardium being
dark grey), borderline abnormal defect (=1; myocardium
being light grey), or normal perfusion (=0; myocardium
being bright). Additional criteria indicative for true
hypoperfusion vs. artifacts were subendocardial signal
reduction persisting longer than the CM first-pass
through the LV cavity, signal reduction in several slices
and neighboring regions [2]. For this ROC analysis the
gradings of all 16 segments of a heart were summed up
and the resulting gradings of the 3 readers were averaged
(referred to as “summed grading”) to enter the ROC
analyses (e.g. individual gradings of a study by readers
1–3 of 14, 18, 16 yield a “summed grading” of 16 for this
study). Of note, the grading categories 0–3 were not
used to assess the data quality, but severity of perfusion
defects. Regarding data quality (predominantly deter-
mined by the presence or absence of breathing motion
and triggering artifacts), a patient was excluded from
analyses, if all 3 readers assessed ≥1 segment as non-
diagnostic in a patient with all other segments normal. If
only 1 or 2 readers found non-diagnostic segments, the
gradings of the readers which judged all segments as
diagnostic were averaged and thus, these examinations
were kept in the analyses. These criteria were implemen-
ted to avoid a selection bias towards high-quality data.
In analogy to the SPECT readings (of stress and rest, i.e.
redistribution images), the blinded readers for CMR
were presented with the stress perfusion images together
with the late enhancement images (i.e. redistribution
images) demonstrating viable and scar tissue. As in pre-
vious trials [1-3], the summed gradings were calculated
from the stress perfusion images only, since differenti-
ation into ischemia and scar tissue was not the primary
aim of the study.
To demonstrate the dependence of the primary end-
point analysis on the selection of threshold, the sensitiv-
ity and specificity scores were also calculated for the
thresholds at summed gradings of 19, 21, and 23, which
were located at the upper left portion of the ROC curve.
SPECT
Stress and rest SPECT examinations were performed as
reported elsewhere [16] according to generally accepted
guidelines [19] on machines of different vendors (2 or 3
head cameras) with 99mTc- or 201Tl-tracers, adenosine
dose as for perfusion-CMR, or physical stress, and 1 or
2 days protocols. The patients had to refrain from coffee,
tea, chocolate or other caffeinated beverages and food
for at least 24 h before the SPECT exam. Gated-SPECT
using 99mTc-tracers was strongly recommended, but
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if part of the performing institution’s clinical routine. In
the efficacy population, i.e. all 3 methods completed,
gated-SPECT was performed in 253 patients. 201Tl-
tracer was used in 32 patients (rest and stress) and in 8
additional patients for rest studies only (6.9% and 1.7%,
respectively). Algorithms for attenuation correction or
resolution recovery were not applied as these were not
available or not identical over all sites.
SPECT data were analyzed visually by 3 blinded read-
ers using a core laboratory (Beacon Bioscience, Inc.
Doylestown, USA). The 3 readers were blinded with re-
spect to any clinical information of the patients or
results of the other examinations. Each reader was pre-
sented with 10–12 short-axis as well as 6–9 vertical and
horizontal long-axis images for both, stress and rest con-
dition. Gated-SPECT data were also presented to the
readers, if they had been acquired. For the ROC analysis
perfusion deficits were graded in each of the 16 seg-
ments as fully reversible (=3), partially reversible (=2),
fixed defect (=1), or normal (=0), and summed gradings
(averaged for the 3 readers) were calculated as for the
CMR analyses. If all 16 segments were normal (summed
grading = 0), but other pathologies were present such as
transient ischemic dilation or exclusive apical ischemia a
summed grading of 3 was assigned. Patients with ≥1 seg-
ment graded as non-diagnostic were treated as for the
CMR examination. The primary endpoint results (=bin-
ary readings according regulatory requirements) were
reported previously [16].
Statistical analysis
Sample size calculations for the primary endpoints were
reported previously [16]. For the comparison of CMR vs.
SPECT by ROC analysis, estimates suggested a required
sample size of ~370 patients to yield an 90% power to
detect a difference in AUC of 0.10 (AUC 0.75 vs. 0.85
for SPECT and CMR, respectively [2]) at a one-sided P-
value of 0.05 [20]. Unlike the sensitivity-specificity ap-
proach used for the primary endpoint, the ROC analysis
approach used for the secondary endpoints assesses sen-
sitivity and specificity “simultaneously” thereby taking
into account, that sensitivity and specificity of a test are
inversely related [17].
ROC analyses were performed for both modalities on
a patient basis (Rockit 0.9.1Beta). AUCs for CMR and
SPECT were compared by a univariate z-score test (null
hypothesis: data sets arose from binormal ROC curves
with equal areas beneath them). In addition to the ana-
lyses of all patients (1–3 vessel disease), MVD patients
were analyzed by exclusion of patients with single vessel
disease. AUCs were also calculated for the male and fe-
male populations separately. After exclusion of patients
with prior MI, AUCs were calculated for the entire studypopulation and the MVD population. All tests were two-
sided and a p-value <0.05 was considered statistically
significant.
Results
Patient characteristics
From the 533 patients enrolled 515 received the MR CM
and entered the safety analysis (the frequency of mild to
moderate adverse events was 22.1% occurring in 74
patients). As reported earlier, this MR-IMPACT II con-
firms the high safety profile of the CMR technique, as
no severe adverse events occurred among the 515
patients [16].
Of the 465 patients with data of all 3 modalities
complete (Table 1 and Figure 1), 227 (48.8%) had coron-
ary artery stenoses with ≥50% diameter reduction, 73
had occlusions (15.7%), 129 (27.7%) had infarctions, and
25 patients (5.4%) of those with infarctions showed no
significant stenoses (<50% diameter reduction) on CXA.
Prevalence of CAD in the population without a history
of infarction was 29%. No patients of the previous MR-
IMPACT I were included in the analyses of MR-
IMPACT II.
Results of ROC analyses
Twenty-six CMR studies (5.6% of 465) and 17 SPECT
studies (3.7% of 465, p = 0.21 vs CMR) were deemed
non-evaluable by the MR and SPECT readers, respect-
ively (Figure 2). Prevalence of CAD in the entire study
population was 60% and 39% for men and women, re-
spectively (p = 0.0002).
The ROC analyses as shown in Figure 2A demonstrate
a higher AUC, i.e. a higher diagnostic performance, of
CMR vs SPECT (entire population: 0.75 ± 0.02 vs
0.65 ± 0.03,p = 0.0004) and vs gated-SPECT (0.69 ± 0.03,
p = 0.018, 201Tl-studies excluded). Similar results were
obtained for the MVD population as shown in
Figure 2B. Figure 3A/B shows superiority of perfusion-
CMR over SPECT in men and women, respectively.
Perfusion-CMR was also superior versus gated-SPECT
in the patient population without prior MI (CMR: AUC
0.69 ± 0.04 vs 0.57 ± 0.04, p = 0.0054, n = 186 in all non-
MI patients; CMR: AUC 0.78 ± 0.04 vs 0.65 ± 0.05,
p = 0.015, n = 140 in MVD non-MI patients, 201Tl-studies
excluded). Similar AUCs were obtained for the different
readers ranging from 0.72 to 0.83 for the CMR readers
and from 0.63 to 0.73 for the SPECT readers (Table 2).
Sensitivity and specificity scores for CMR (for details
see reference [16]) were also calculated at the threshold
of best test performance (i.e. at a summed grading of 21,
see Figure 2A) and demonstrated non-inferiority for
CMR for both, sensitivity and specificity primary end-
points with a lower confidence level for the difference
(ΔLCL) of −0.05 and −0.08, respectively (i.e. the lower
Table 1 Demographics of study population
n (%)
Patients enrolled and CM administered:1 515
Male sex 377 (73.2)
Age (mean±SD) 60±10.3 years
Body mass index (mean±SD) 28.2±4.3 kg/m2
Risk factors:
Hypertension 358 (69.5)
Hypercholesterolemia 354 (68.8)
Diabetes 92 (17.8)
History of heart failure 106 (20.6)
Myocardial infarction 139 (27.0)
Percutaneous coronary intervention (PCI) 170 (33.0)
Angina pectoris 414 (80.4)
CCS I 87 (16.9)
CCS II 227 (44.1)
CCS III 46 (8.9)
CCS IV 21 (4.1)
Patients with all 3 test data sets complete
(efficacy population):
n 465
Coronary artery disease 227 (48.8)
Left main 14 (3.0)
LAD 134 (28.8)
LCX 104 (22.4)
RCA 112 (24.1)
Multivessel disease 113 (24.3)
Myocardial infarction 129 (27.7)
Medication:
Any drugs 496 (96.4)
Beta-blockers 367 (71.3)
Lipid lowering 354 (68.8)
Angiotensin-converting enzyme inhibitors 306 (59.4)
Diuretics 131 (25.5)
Calcium channel blockers 99 (19.2)
Antithrombotic 425 (82.6)
MR – not evaluable 26 (5.6)
SPECT – not evaluable 17 (3.7)
CCS: Canadian Cardiovascular Society; LAD: left anterior descending coronary
artery; LCX: left circumflex coronary artery; RCA: right coronary artery.
1 Eighteen patients were recruited but did not receive MR contrast medium,
for reasons, see Flow chart in Figure 1.
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ity and specificity scores fall within the equivalence
margin <10% vs SPECT). At a summed grading of
19 (see Figure 1A, dot to the right on the ROC
curve), CMR is read at a low threshold for perfusion
deficits and achieves superior sensitivity vs SPECT
(ΔLCL of +0.01), but is of inferior specificity (ΔLCLis −0.14). Conversely, at a summed grading of 23 (see
Figure 2A), i.e. at a high threshold for CMR reading (grad-
ing=23), CMR is inferior for sensitivity vs SPECT (ΔLCL
is −0.11), but achieves non-inferiority for specificity (ΔLCL
is −0.04).
Performance in patients with pharmacological and
physical stress
During the SPECT studies, 162 patients were stressed by
exercise. In this subgroup the AUC for the SPECT tech-
nique was 0.67 ± 0.04 (which was similar in comparison
of the entire SPECT population with 0.65 ± 0.03), but
performance was lower compared with CMR of
0.75 ± 0.04 (p = 0.035, n = 147). AUC for SPECT with
pharmacological stress was 0.64 ± 0.03, which was lower
compared with CMR (AUC: 0.74 ± 0.02, p = 0.0015).
Discussion
The main results of the trial can be summarized as fol-
lows: 1). The diagnostic performance of perfusion-CMR
assessed as the area under the ROC curve was superior
over SPECT in detecting CAD when assessed in the en-
tire study population, and 2). Perfusion-CMR was also
superior (higher AUC) for CAD detection in the sub-
groups analyzed such as in patients with gated-SPECT
and non-gated-SPECT, in patients with multi-vessel dis-
ease, in men as well as in women, and in the patients
without prior MI.
Perfusion-CMR and SPECT comparison
The current MR-IMPACT II results are well in line with
a previous perfusion-CMR multicenter study [3]. The
mean AUC for the CM doses of 0.05 and 0.1 mmol/kg
in a previous smaller multicenter study was 0.79 which
is close to the 0.75 in MR-IMPACT II. Diagnostic per-
formance in the MR-IMPACT II with an AUC of 0.75
was slightly lower than in MR-IMPACT I with an AUC
of 0.86. This might be related to the larger number of
participating sites in MR-IMPACT II, by which less
experienced centers could have contributed to the data.
Also, in MR-IMPACT II a slightly lower CM dose of
0.075 mmol/kg was used than the most effective dose in
MR-IMPACT I of 0.10 mmol/kg (for regulatory pur-
poses the lowest efficacious dose was tested). With 33
participating sites in US and Europe, this MR-IMPACT
II is to our knowledge the CMR study on myocardial is-
chemia with the highest number of contributing centers
conducted so far. Since these centers participated with
various CMR systems and drop-out rate was kept as low
as 5.6%, the study results are assumed to adequately re-
flect the performance and robustness of perfusion-CMR
in the day-to-day clinical setting. Results of the so far
largest single center perfusion-CMR trial called CE-
MARC were published recently [9]. In CE-MARC 752
Withdrawals/Drop-outs 
Patient-related: n=6 
 
4: Lost to follow-up  
1: Unstable angina 
1: Vomiting due to adenosine  
1: IV lines not available 
Withdrawals/Drop-outs 
Technical: n=44 
 
16: CXA not evaluable 
10: SPECT not done 
  7: CXA not done 
  5: CMR not done 
  5: dose of stress agent and/or 
      CM or tracer not according   
      protocol 
  1: Withdrawal due to technical  
      problems 
 
Patients received  
MR contrast medium:  
n=515 
 
Patient 
Recruitment 
n=533 
CMR: Inadequate quality 
Patients excluded: 26 
SPECT: Inadequate quality 
Patients excluded: 17 
Withdrawal/drop-outs 
Patient-related: n=18 
 
8: Claustrophobia, Anxiety 
2: Not fit to MR scanner 
2: Subject request 
1: Abnormal laboratory test result 
1: Atrial fibrillation 
1: Hearing problem 
1: Medical condition 
1: Over recruitement 
1: IV lines not available 
Patients available 
for Analyses 
Data of all 
3 modalities complete: 
n=465 
Patients included  
into Analyses 
Data of all 3 modalities  
evaluable: n=425 
Figure 1 Flow Chart. Flow chart demonstrating the number of eligible patients and drop-outs. CMR: cardiovascular magnetic resonance; CM:
contrast medium (Gd-DTPA-BMA); CXA: coronary X-ray angiography; Pats: patients. SPECT: single-photon-emission-computed-tomography.
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perfusion-CMR, a gated-SPECT, and CXA. In the 628
patients who completed all three tests, diagnostic per-
formance of CMR was superior to SPECT to detect
>50% diameter stenosis on CXA with AUCs of 0.84 ver-
sus 0.69 (p < 0.0001). Of note, in CE-MARC perfor-
mances for both, perfusion-CMR and gated-SPECT were
similar to those obtained in the current multicenter MR-
IMPACT II. These results of the MR-IMPACT II
underline the strengths of the perfusion-CMR tech-
nique. Correction of cardiac and breathing motion with
ECG-triggering and breath-holding, respectively, appears
to reliably minimize motion-related artifacts as less than
6% of data had to be excluded from analyses due to in-
adequate quality. This approach preserves the nominally
high spatial resolution of perfusion-CMR and thereby
allows detecting small even subendocardial perfusion
deficits. Moreover, as with any MR acquisition, the MR
perfusion images are not compromised by signal attenu-
ation artifacts which could be perceived as perfusion
deficits.
SPECT imaging also proved to be robust over the 33
centers and the SPECT results of this trial are in close
match which those of MR-IMPACT I with AUC of 0.65
vs 0.67, respectively. The SPECT results are also well in
line with CE-MARC and other previous multicenter
SPECT trials [18,21-23] with sensitivities (ranging from
77% to 87% vs CXA) and specificities (ranging from 36%
to 58% vs CXA) being located very closely to the ROC
curve of the current MR-IMPACT II. Of note, also
higher specificities for the SPECT technique were
reported in single center studies.When comparing the AUCs for perfusion-CMR and
SPECT, superiority of CMR was achieved versus the en-
tire SPECT population (p = 0.0004, n = 425) as well as
for the gated-SPECT population (p = 0.018, n = 253).
When assessing the diagnostic performances (=AUCs) of
both, CMR and SPECT, it should be kept in mind that
the readings were performed in a fully blinded fashion
without integrating any clinical information of the
patients which is likely to result in underestimation of
the clinical diagnostic performance of these imaging
techniques.
Performance of perfusion-CRM in multivessel disease
patients, in patients without prior MI, and in men and
women
As patient prognosis is coupled to the extent of ische-
mia, it is important to note, that the diagnostic superior-
ity of perfusion-CMR was also preserved in the MVD
patients as shown in Figure 2B.
In the study by Lin and coworkers [24], women were
less likely to undergo stress testing prior to PCI com-
pared with men and other studies demonstrated, that
younger women had a worse outcome after acute MI
compared to age-matched men [25]. These findings go
along with particular difficulties in women for ischemia
detection, as breast tissue can cause suboptimal imaging
conditions. Also, women are more susceptible to radi-
ation sequelae in terms of cancer incidence [26,27].
Therefore, a radiation-free test for ischemia detection in
women is particularly valuable. The results of MR-
IMPACT II demonstrate equal diagnostic performance
of CMR irrespective of gender, which was superior to
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Figure 2 Diagnostic performance in the entire study population – ROC analyses. Diagnostic performance of perfusion-CMR and SPECT
imaging compared by receiver operating characteristics curves (ROC) analyses for detection of CAD (per patient analysis). A). CMR performs
superior to all SPECT studies in 1–3 vessel disease (1–3 VD) patients and is also superior to the gated-SPECT and ungated-SPECT groups.
Difference in AUC between gated-SPECT and ungated-SPECT did not reach statistical significance. The dots on the ROC curve for CMR indicate
the sensitivities and specificities for various thresholds (i.e. at summed gradings of 23 [dot on the left], 21 [middle dot], and 19 [dot on the right])
with + and – indicating superiority and inferiority vs SPECT, respectively, and= indicating non-inferiority versus SPECT for both, sensitivity and
specificity, as defined as primary end-point of the study (for details on the definition of the primary endpoint see reference [16]). These dots
located at various reading thresholds illustrate that comparisons for sensitivity and specificity depend on the thresholds applied for the 2 tests.
Thus, for the same data set, superiority or inferiority can be obtained (for sensitivity or specificity comparisons) depending on the reading
thresholds used. Reading CMR studies at a high threshold for perfusion deficits (point on the left on the ROC curve) yields CMR inferiority for
sensitivity and CMR non-inferiority for specificity vs SPECT, while the same CMR test read with a low threshold (point on the right of the ROC
curve) yields a superior sensitivity for CMR vs SPECT with inferiority for specificity. This dependence of comparisons upon reading thresholds is
eliminated by the ROC approach, which assesses test performance over the entire range of reading thresholds. B): Perfusion-CMR is superior to
SPECT in multi-vessel disease patients. Sub-group analyses for gated-SPECT and ungated-SPECT yielded superiority for CMR, as well.
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http://www.jcmr-online.com/content/14/1/61SPECT in both, men and women (Figure 3A/B). While
multicenter data for SPECT in women are rare, one
study [21] yielded 95%-confidence intervals for sensitiv-
ity and specificity of 69-100% and 10-61%, respectively,
which fall onto the SPECT-ROC curve for women of the
current study. Similarly, a single center study using thal-
lium SPECT found a lower diagnostic performance in
women versus men, which was related to smaller heart
sizes in women [28]. As spatial resolution of perfusion-
CMR is higher than in SPECT and attenuation artifacts
do not occur, it is not surprising that two earlier single
center studies found a similar performance of CMR in
women and men [29,30], which is well in line with the
current multicenter findings.
For CMR image interpretation, only the stress perfu-
sion images were used, but the readers were exposed tothe viability images obtained by applying the late en-
hancement CMR technique. To test, whether viability
information could have played a major role in the recog-
nition of ischemia, a sub-analysis was performed which
excluded the patients with prior MI. This reduced the
sample size to 174, but the difference in AUC persisted
in favor of CMR (with a p-value of 0.0054).
Limitations of the study
The definition of CAD applied in this study was primar-
ily dependent on coronary anatomy (in most patients by
fulfilling the criterion of a ≥50% diameter stenosis in a
≥2 mm vessel and in a minority of patients by the his-
tory of MI, even when the infarct-related vessel was
non-stenosed after PCI). This anatomy-based definition
does not consider collateral flow and microcirculatory
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Figure 3 Diagnostic performance in men and women – ROC analyses. Perfusion-CMR is superior vs SPECT in both, men (A) and women (B).
Numbers indicate mean± standard error of the AUC.
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http://www.jcmr-online.com/content/14/1/61factors that modify the hemodynamic relevance of epi-
cardial stenoses. Nevertheless, this definition was
deemed best as it is relatively easy to measure, is fre-
quently used in such comparative studies, and it often
sets the basis for patient management in clinical routine.
In this context is should be noted that an optimal pa-
tient management should always consider the patient’s
symptoms, his risk factor profile, and the prognosis
(derived from risk factors, symptoms, and imaging
information).Table 2 Areas under the Receiver-Operator Characteristics Cu
AUC - CMR
Sub-study 1 (n = 238) mean AUC LCL UCL
Reader A 0.72 0.63 0.80
Reader B 0.79 0.72 0.85
Reader C 0.75 0.67 0.82
Range for AUC 0.07 - -
Sub-study 2 (n = 227)
Reader A 0.76 0.68 0.82
Reader B 0.83 0.77 0.88
Reader C 0.75 0.68 0.81
0.08 - -The aim of this study was to assess the diagnostic per-
formance of CMR and SPECT to identify patients with
CAD through the detection of perfusion abnormalities.
Once CAD is identified, a further evaluation is recom-
mended to assess scar tissue. As the late enhancement
CMR technique is well documented as a robust and pre-
cise method to detect scar [31,32], this additional work-
up was not tested in this trial. We would like to stress,
however, that perfusion testing should be accompanied
in general by a viability testing, particularly in patientrves (AUC) for all readers
AUC - SPECT Δ - AUC
mean AUC LCL UCL CMR vs SPECT
0.63 0.53 0.72 +0.09
0.70 0.62 0.77 +0.09
0.63 0.53 0.73 +0.12
0.07 - - -
0.69 0.61 0.76 +0.07
0.69 0.60 0.76 +0.14
0.73 0.64 0.80 +0.02
0.04 - - -
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http://www.jcmr-online.com/content/14/1/61with reduced LV function, to allow for an optimal patient
management. To explore a potential influence of scar tis-
sue on the study results, the ROC analysis was repeated in
the patient population without prior MI and superiority of
CMR over SPECT was preserved (p= 0.0054).
In this trial patients with decompensated heart failure,
after bypass surgery, and with relevant arrhythmias were
excluded, and thus, the findings of this study should not
be applied to these patient groups. Due to the inclusion
criteria, the frequency of CAD was relatively high with
48.8% in this trial. While this rather rigorous recruit-
ment strategy represents a strength of the trial, the trial
results cannot be extrapolated to other populations with
lower disease prevalence, e.g. to asymptomatic screening
populations.
While this study shows that perfusion-CMR is useful
for the detection of CAD, further studies will be needed
to address the question, whether this perfusion informa-
tion when used to guide revascularizations also improves
outcome in comparison to other non-invasive methods
that test ischemia.
Conclusions
This large international, multicenter, multivendor, pro-
spective trial performed at 33 centers and including 465
patients shows perfusion-CMR as superior to gated-
SPECT for the detection of CAD when comparing test
performance by ROC analysis. Perfusion-CMR was also
superior to SPECT in detecting CAD in men as well as
in women. Perfusion-CMR can be recommended as an
alternative for SPECT imaging.
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